Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
613.45 -12.15 (-1.94%) 11:06 ET [NASDAQ]
612.60 x 1 613.78 x 47
Realtime by (Cboe BZX)
612.60 x 1 613.78 x 47
Realtime 602.60 -23.00 (-3.68%) 08:49 ET
Quote Overview for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
613.15
Day High
627.22
Open 626.25
Previous Close 625.60 625.60
Volume 187,287 187,287
Avg Vol 970,207 970,207
Stochastic %K 10.87% 10.87%
Weighted Alpha -40.60 -40.60
5-Day Change -18.71 (-2.94%) -18.71 (-2.94%)
52-Week Range 610.10 - 1,211.20 610.10 - 1,211.20
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,393,712
  • Shares Outstanding, K 109,325
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,991 M
  • EBITDA $ 4,474 M
  • 60-Month Beta 0.44
  • Price/Sales 4.75
  • Price/Cash Flow 13.50
  • Price/Book 2.30

Options Overview Details

View History
  • Implied Volatility 43.47% ( +2.21%)
  • Historical Volatility 32.14%
  • IV Percentile 99%
  • IV Rank 96.55%
  • IV High 44.40% on 01/10/25
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 0.53
  • Today's Volume 153
  • Volume Avg (30-Day) 1,456
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 38,686
  • Open Int (30-Day) 37,246

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 6.88
  • Number of Estimates 5
  • High Estimate 7.91
  • Low Estimate 5.67
  • Prior Year 7.97
  • Growth Rate Est. (year over year) -13.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
610.10 +1.15%
on 04/02/25
Period Open: 684.87
748.29 -17.53%
on 03/10/25
-67.75 (-9.89%)
since 03/03/25
3-Month
610.10 +1.15%
on 04/02/25
Period Open: 718.15
748.29 -17.53%
on 03/10/25
-101.03 (-14.07%)
since 01/03/25
52-Week
610.10 +1.15%
on 04/02/25
Period Open: 950.95
1,211.20 -49.05%
on 08/27/24
-333.83 (-35.10%)
since 04/03/24

Most Recent Stories

More News
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

TECH : 55.29 (-5.29%)
VRTX : 482.41 (-0.22%)
MRNA : 26.33 (-5.01%)
REGN : 613.09 (-2.00%)
XBI : 77.64 (-3.66%)
Stocks Finish Higher as Magnificent Seven Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.82%. June E-mini S&P...

ALK : 46.44 (-9.19%)
GOOGL : 151.02 (-3.83%)
UAL : 62.02 (-13.10%)
AAPL : 203.87 (-8.94%)
PVH : 67.28 (-13.56%)
ADI : 183.95 (-7.84%)
JNJ : 159.88 (+2.91%)
MRK : 87.60 (+1.15%)
TXN : 168.49 (-5.44%)
$IUXX : 18,608.69 (-4.97%)
PFE : 24.72 (+0.08%)
ZNM25 : 112-290 (+1.26%)
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

REGN : 613.09 (-2.00%)
SNY : 55.24 (+2.39%)
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...

MRK : 87.60 (+1.15%)
REGN : 613.09 (-2.00%)
AMGN : 308.86 (+1.03%)
AXSM : 108.17 (-1.44%)
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

REGN : 613.09 (-2.00%)
3 Reasons to Sell REGN and 1 Stock to Buy Instead

3 Reasons to Sell REGN and 1 Stock to Buy Instead

COST : 965.44 (+0.04%)
REGN : 613.09 (-2.00%)
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...

NVS : 113.46 (+2.43%)
REGN : 613.09 (-2.00%)
PFE : 24.72 (+0.08%)
SNY : 55.24 (+2.39%)
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

NTRA : 136.99 (-4.34%)
EXAS : 44.23 (-0.74%)
INCY : 61.55 (-1.25%)
REGN : 613.09 (-2.00%)
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

ORLY : 1,436.22 (+1.36%)
REGN : 613.09 (-2.00%)
HSY : 164.38 (+0.26%)
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...

ALNY : 259.51 (-2.74%)
NVS : 113.46 (+2.43%)
REGN : 613.09 (-2.00%)
RHHBY : 40.8200 (+3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 650.27
2nd Resistance Point 639.13
1st Resistance Point 632.37
Last Price 613.09
1st Support Level 614.47
2nd Support Level 603.33
3rd Support Level 596.57

See More

52-Week High 1,211.20
Fibonacci 61.8% 981.58
Fibonacci 50% 910.65
Fibonacci 38.2% 839.72
Last Price 613.09
52-Week Low 610.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades